Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific corporate action regarding share repurchases executed on July 29, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to treasury shares.
- Shares Purchased: 875,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,378.5 pence per share; lowest price paid was 1,365.5 pence per share.
- Treasury Holdings (Settled): 494,796,816 shares (8.83% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,521,816 shares (9.74% of total voting rights).
- Shares in Issue: 5,110,074,101 shares (excluding treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 875,000 shares for treasury. This action increased the percentage of total voting rights held in treasury to 9.74% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves strictly as a notification of the share buyback transaction and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in treasury (494,796,816 settled) against the company's latest capitalization table.
- Confirm the percentage of voting rights held in treasury (9.74% including unsettled shares) for disclosure threshold calculations under FSA rules.
- Check the total shares in issue (5,110,074,101) to ensure accurate denominator usage for shareholder interest notifications.
- Review the price range paid (1,365.5 to 1,378.5 pence) to assess the cost of capital reduction relative to market prices on July 29, 2011.